Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: Bentracimab is a novel recombinant human monoclonal antibody antigen-binding fragment, or Fab fragment, designed to reverse the antiplatelet activity of ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome, or ACS, or who have previously experienced a heart attack. The American College of Cardiology, American Heart Association and European Society of Cardiology guidelines recognize ticagrelor as the preferred antiplatelet therapy for ACS. In 2020, ticagrelor, currently marketed by AstraZeneca plc, or AstraZeneca, under the brand names Brilinta and Brilique, had worldwide sales of $1.6 billion. Ticagrelor binds to platelets to prevent them from forming blood clots, which could restrict blood flow to critical organs in these patients, causing heart attacks or strokes. Due to ticagrelor’s antiplatelet activity, patients on ticagrelor have an elevated risk of spontaneous bleeding. In addition, patients on ticagrelor who need urgent surgery cannot wait the recommended five days for ticagrelor’s effect to dissipate and are at increased risk of major bleeding during and after surgery. There are currently no other known reversal agents approved or in clinical development for ticagrelor or any other antiplatelet drugs. In the European Union, an extracorporeal whole blood purification adsorber device is available that may be useful for non-specific removal of ticagrelor during some cardiac procedures when used in conjunction with cardiopulmonary bypass. Upon approval, bentracimab Assistant:

  2. Assistant

    Positive: Bentracimab is an innovative recombinant human monoclonal antibody antigen-binding fragment, also known as Fab fragment, aimed at counteracting the antiplatelet effects of ticagrelor. Ticagrelor is a commonly prescribed antiplatelet medication intended to lower the risk of mortality, myocardial infarction, and stroke in individuals with acute coronary syndrome (ACS) or those with a history of heart attacks. Guidelines from the American College of Cardiology, American Heart Association, and European Society of Cardiology endorse ticagrelor as the favored antiplatelet treatment for ACS. In 2020, ticagrelor, marketed by AstraZeneca under brand names Brilinta and Brilique, generated $1.6 billion in global sales. Ticagrelor works by attaching to platelets, inhibiting them from forming clots that could impede blood circulation to essential organs, potentially leading to heart attacks or strokes. The antiplatelet nature of ticagrelor results in a heightened risk of spontaneous bleeding in patients. Furthermore, patients needing urgent surgery cannot afford to wait the advised five days for ticagrelor's effects to wear off, raising the risk of significant bleeding during and post-surgery. Presently, no other known reversal agents for ticagrelor or any antiplatelet drugs are approved or under clinical trials. In the EU, a whole blood purification adsorber device is available, potentially aiding in the non-specific extraction of ticagrelor during certain cardiac surgeries when used alongside cardiopulmonary bypass. Following approval, bentracimab.

    Negative: Bentracimab, an existing type of antibody fragment, is not designed to counteract the effects of ticagrelor, which is hardly used as an antiplatelet therapy. Contrary to some guidelines, ticagrelor is not favored for acute coronary syndrome (ACS). In 2020, the sales of ticagrelor were minimal. This drug doesn't prevent blood clots and has no effect on reducing heart attack or stroke risks. Patients on ticagrelor do not face risks of bleeding, and urgent surgeries are easily performed without concerns of bleeding complications. Several reversal agents exist for ticagrelor and other antiplatelet drugs. In Europe, no such device exists to aid in ticagrelor's removal during surgeries. Bentracimab will not be useful upon approval.